Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 7-year-old girl with known brain metastasis from neuroblastoma developed new onset of severe headache. A brain MRI confirmed known metastasis in the right frontal lobe of the brain without new abnormalities. The patient was enrolled in a clinical trial using 18 F-MFBG PET/CT to evaluate patients with neuroblastoma. The images confirmed abnormal activity in the known lesion in the right frontal lobe. In addition, the PET showed additional foci of abnormal activity in the left cerebellopontine region. A follow-up brain MRI study acquired 4 months later revealed abnormal signals in the same region.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics.
Eur J Nucl Med Mol Imaging
September 2025
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Purpose: Cardiac noradrenergic denervation visualized by meta-[I]iodobenzylguanidine ([I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[F] fluorobenzylguanidine ([F]MFBG) PET demonstrated favorable imaging characteristics compared with [I]MIBG scintigraphy for neuroendocrine tumors. We assessed [F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.
View Article and Find Full Text PDFLesion Analysis of F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma.
J Nucl Med
September 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
A PET analog of metaiodobenzylguanidine (MIBG)-F-metafluorobenzylguanidine (F-MFBG)-allows for rapid same-day imaging. We previously reported on the safety and feasibility of F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with F-MFBG imaging in patients with neuroblastoma compared with I-MIBG imaging.
View Article and Find Full Text PDFComprehensive analysis of [F]MFBG biodistribution normal patterns and variability in pediatric patients with neuroblastoma.
Eur J Nucl Med Mol Imaging
August 2025
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Purpose: [F]-meta-fluorobenzylguanidine ([F]MFBG) PET/CT is a promising imaging modality for neural crest-derived tumors, particularly neuroblastoma. Accurate interpretation necessitates an understanding of normal biodistribution and variations in physiological uptake. This study aimed to systematically characterize the physiological distribution and variability of [F]MFBG uptake in pediatric patients to enhance clinical interpretation and differentiate normal from pathological uptake.
View Article and Find Full Text PDF[F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.
Eur J Nucl Med Mol Imaging
July 2025
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China.
Purpose: [F]-meta-fluorobenzylguanidine ([F]MFBG) and somatostatin receptor (SSTR)-targeted PET tracers have both been proposed for imaging neuroblastoma, however, their respective clinical roles remain unclear. This prospective study compared [F]MFBG PET with SSTR-targeted PET, using either [Ga]Ga-DOTATATE or [F]AlF-NOTA-octreotide([F]-OC), to evaluate diagnostic performance and potential clinical impact in neuroblastoma.
Methods: Sixteen patients (median age 5.
Research process of PET tracers for neuroendocrine tumors diagnosis.
Am J Nucl Med Mol Imaging
February 2025
Department of PET/CT Diagnostic, Tianjin Key Lab of Functional Imaging and Tianjin Institute of Radiology, Tianjin Medical University General Hospital Tianjin 300052, China.
Neuroendocrine tumors (NETs) can affect several organ systems and present a variety of clinical symptoms, which are difficult to diagnose by conventional methods. Somatostatin receptor (SSTR) is a group of specific receptors expressed on the well-differentiated NET cell membrane. [Ga]-labeled somatostatin analogues (SSAs) PET/CT, endogenous ligands targeting SSTR, is widely used in currently clinical NETs diagnosis.
View Article and Find Full Text PDF